These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 10941600

  • 21. Apolipoproteins A1 and B levels and serum cholinesterase activity in hyperlipidemic subjects.
    Olinic D, Stoia M, Marian I, Trif I, Cucuianu M.
    Rom J Intern Med; 1999; 37(1):71-9. PubMed ID: 15523947
    [Abstract] [Full Text] [Related]

  • 22. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
    Paragh G, Seres I, Harangi M, Erdei A, Audikovszky M, Debreczeni L, Kovácsay A, Illyés L, Pados G.
    Br J Clin Pharmacol; 2006 Jun; 61(6):694-701. PubMed ID: 16722831
    [Abstract] [Full Text] [Related]

  • 23. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
    Dinkel RE, Barrett PH, Demant T, Parhofer KG.
    Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
    [Abstract] [Full Text] [Related]

  • 24. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M, Zák A, Vecka M, Romaniv S.
    Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of antiatherogenic L-aspartate and L-glutamate on serum lipoproteins cholesterol and apolipoproteins A-1 and B in rabbits fed with high cholesterol diet.
    Yanni AE, Perrea DN, Yatzidis HA.
    Nutr Metab Cardiovasc Dis; 2005 Jun; 15(3):161-5. PubMed ID: 15955463
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats.
    Rao MS, Papreddy K, Musunuri S, Okonkwo A.
    In Vivo; 2002 Jun; 16(2):145-52. PubMed ID: 12073774
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [The abnormal changes of apolipoprotein(s) in patients with type 2 diabetes mellitus].
    Ren Y, Tian H, Liu B, Liang J, Zhang X, Yao J, Xu Y.
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Mar; 32(1):48-51, 69. PubMed ID: 12733353
    [Abstract] [Full Text] [Related]

  • 31. [Separation of lipoproteins as a function of their apolipoprotein composition. Clinical applications].
    Fruchart JC.
    Ann Biol Clin (Paris); 1986 Mar; 44(2):116-21. PubMed ID: 3092704
    [No Abstract] [Full Text] [Related]

  • 32. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III.
    Dallinga-Thie GM, Bu XD, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TW.
    J Lipid Res; 1996 Jan; 37(1):136-47. PubMed ID: 8820109
    [Abstract] [Full Text] [Related]

  • 33. Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.
    Hsu HC, Lee YT, Yeh HT, Chen MF.
    J Lab Clin Med; 2001 Jun; 137(6):414-21. PubMed ID: 11385362
    [Abstract] [Full Text] [Related]

  • 34. Changes in serum apolipoprotein and lipoprotein profile after alcohol withdrawal: effect of apolipoprotein E polymorphism.
    Gueguen S, Herbeth B, Pirollet P, Paille F, Siest G, Visvikis S.
    Alcohol Clin Exp Res; 2002 Apr; 26(4):501-8. PubMed ID: 11981126
    [Abstract] [Full Text] [Related]

  • 35. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
    Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fiévet C, Lefebvre P, Staels B.
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):585-91. PubMed ID: 15618549
    [Abstract] [Full Text] [Related]

  • 36. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M, Nowicka G, Szostak WB, Kłosiewicz-Latoszek L.
    Kardiol Pol; 1982 Mar; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
    Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT.
    Am J Cardiol; 2008 Aug 15; 102(4):434-9. PubMed ID: 18678301
    [Abstract] [Full Text] [Related]

  • 38. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia.
    Paragh G, Balla P, Katona E, Seres I, Egerházi A, Degrell I.
    Eur Arch Psychiatry Clin Neurosci; 2002 Apr 15; 252(2):63-7. PubMed ID: 12111338
    [Abstract] [Full Text] [Related]

  • 39. Apolipoproteins AI and B as therapeutic targets.
    Charlton-Menys V, Durrington P.
    J Intern Med; 2006 May 15; 259(5):462-72. PubMed ID: 16629852
    [Abstract] [Full Text] [Related]

  • 40. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
    Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ, FIELD study investigators.
    Arterioscler Thromb Vasc Biol; 2009 Jun 15; 29(6):950-5. PubMed ID: 19325138
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.